Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Pfizer Japan to Launch 2 Generic APIs on Feb 8, Total 18 APIs
February 6, 2012
- OncoTherapy to Jointly Initiate PIII Study for OCV-C01 with Otsuka
February 6, 2012
- US, European Pharmaceutical Companies Supported by Steady Japan Business Growth
February 6, 2012
- Lipitor Generics Have Over 6% of Negative Impact: Astellas
February 6, 2012
- Pfizer Highly Rated for Pharmacist Support: Nextit Research Survey
February 6, 2012
- Mr Tsuchiya of Eisai Disapproves Virtual Permission of Off-label Use of Generics Not Approved for the Same Indications as Their Original Drugs
February 6, 2012
- Chugai Pharmaceutical Dec 2011 Sales Decline After Earthquake Despite Steady Sales Abroad
February 6, 2012
- Number of MRs Breaks 60,000; Could Become Major Topic in Light of Strained Healthcare Finances
February 6, 2012
- Eisai Says Impact from Generic Versions of Aricept Insignificant
February 3, 2012
- Eisai's Apr-Dec Sales Down 17% on 50% Drop in Aricept Sales
February 3, 2012
- Pfizer to Offer Financial, Technical Support for Early Stage Development to External Institution
February 3, 2012
- Apr-Dec Sales Up 4%, Profits Show 2-Digit Increase due to Growth in Vesicare: Astellas
February 3, 2012
- Chugai to Restructure Marketing Div. to Achieve Targets in “Sunrise 2012” Plan
February 3, 2012
- New Granule Formulation of Fosrenol Obtains Approval: Bayer Yakuhin
February 3, 2012
- Janssen Files Application for Additional Subcutaneous Administration of Velcade
February 2, 2012
- Chugai Pharmaceutical to Promote Executive VP Kosaka as President and COO
February 2, 2012
- Astellas, UCB Form Partnership for Rheumatoid Arthritis Treatment Awaiting Approval
February 2, 2012
- Kyowa Kirin Sees Nesp as Core of Its Asian Strategy: President Matsuda
February 2, 2012
- Maruho, Asahi Kasei Pharma File Application for Add’l Indication of Herpes Simplex for Famvir
February 2, 2012
- Nycomed Acquisition Contributes to 4.3% Growth in Sales for April-December 2011: Takeda
February 2, 2012
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…